Last reviewed · How we verify

Aflibercept IVT — Competitive Intelligence Brief

Aflibercept IVT (Aflibercept IVT) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: VEGF trap; anti-angiogenic fusion protein. Area: Ophthalmology.

phase 2 VEGF trap; anti-angiogenic fusion protein VEGF-A, VEGF-B, PlGF (placental growth factor) Ophthalmology Biologic Live · refreshed every 30 min

Target snapshot

Aflibercept IVT (Aflibercept IVT) — 4D Molecular Therapeutics. Aflibercept IVT is a vascular endothelial growth factor (VEGF) trap that binds and neutralizes VEGF and placental growth factor (PlGF) to inhibit pathological angiogenesis and vascular permeability.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Aflibercept IVT TARGET Aflibercept IVT 4D Molecular Therapeutics phase 2 VEGF trap; anti-angiogenic fusion protein VEGF-A, VEGF-B, PlGF (placental growth factor)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (VEGF trap; anti-angiogenic fusion protein class)

  1. 4D Molecular Therapeutics · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Aflibercept IVT — Competitive Intelligence Brief. https://druglandscape.com/ci/aflibercept-ivt. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: